A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors

Cancer

Volumn 82, Issue 3, 1998, Pages 561-566

  Bunnell, Craig A ^a   Thompson, Lynn ^a   Buswell, Lori ^a   Berkowitz, Ross ^a   Muto, Michael ^a   Sheets, Ellen ^a   Shulman, Lawrence N ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Granulocyte colony stimulating factor; Ifosfamide; Medical oncology; Paclitaxel; Phase I

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032006267     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19980201)82:3<561::aid-cncr19>3.0.co;2-%23     Document Type: Article

References (10)

1. Antman KH, Montella D, Rosenbaum C, Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 1985;69:499-504.
2. Johnson DH. Overview of ifosfamide in small cell and non-small cell lung cancer. Semin Oncol 1990; 17(2 Suppl 4):24-30.
3. Markman M, Hakes T, Reichman B, Lewis JL, Rubin S, Jones W, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10:243-8.
4. Sutton GP, Blessing JA, Homesley HD, Herman ML, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:1672-6.
5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-7.
6. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
7. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
8. Hall G, Lind MJ, Huang M, Moore A, Gane A, Roberts JT, et al. Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. Postgrad Med J 1990; 66(780):860-1.
9. Cook JA, Fisher J, Teague D, Liebmann J. Sequence dependence of paclitaxel combined with cisplatin or alkylators in human cancer cells [meeting abstract]. Proc Amer Assoc Cancer Res 1994;35:A1975.
10. Rowinsky EK, Gilber MR, McGuire WP, Noe DA, Grochow LB, Forasstiere AA, et al. Sequences of taxol and cisplatin: a Phase I and pharmacologic study. J Clin Oncol 1991;9:1692-703.